Frequently Asked Questions About Grisactin (Griseofulvin)
1.What is Grisactin (Griseofulvin)?
2.How Does Grisactin Work?
3.What Types of Fungal Infections Does Grisactin Address?
4.Is Grisactin Effective for Nail Fungus?
5.How Long Does it Take for Grisactin to Show Results?
6.Can Grisactin Be Used for Systemic Fungal Infections?
7.In What Forms is Grisactin Available?
8.Can Grisactin Tablets be Crushed for Easier Administration?
9.Are There Dietary Restrictions While Taking Grisactin?
10.How is Grisactin Administered?
11.Is Grisactin Safe for Children?
12.Can Grisactin Interact with Other Medications?
13.What Should I Do If I Miss a Dose of Grisactin?
14.Does Grisactin Have Side Effects?
15.Is Alcohol Consumption Safe While Taking Grisactin?
16.Is Grisactin Safe for Pregnant Women?
17.Can Grisactin Cause Allergic Reactions?
18.How Long Should I Take Grisactin?
19.Is Grisactin Safe for Breastfeeding Mothers?
20.What Precautions Should I Take While Using Grisactin?
21.Does Grisactin Affect Birth Control Pills?
22.Is Grisactin Effective Against Candida Infections?
23.Can Grisactin Cause Photosensitivity?
24.Can Grisactin Be Used for Tinea Versicolor?
25.Is Grisactin Effective Against Scalp Ringworm?
26.Can Grisactin Be Used Topically?
27.Can Grisactin Cause Gastrointestinal Distress?
28.Is Grisactin Safe for Individuals with Liver Disease?
29.Can Grisactin Cause Blood Disorders?
30.Can Grisactin Be Used in Conjunction with Other Antifungal Medications?
📚 Sources Used for FAQ Content:
Information on griseofulvin (the active ingredient in Grisactin) is drawn from regulatory approvals across major markets, dermatology and infectious disease treatment guidelines, and clinical experience spanning more than 60 years. Grisactin was originally manufactured by Wyeth-Ayerst (later Wyeth, now Pfizer) as one of the early branded griseofulvin products, and remains in use today particularly for tinea capitis in children and dermatophyte nail infections.- U.S. FDA - Griseofulvin first approved 1959 as the first oral systemic antifungal for dermatophyte infections
- European Medicines Agency (EMA) - Widely approved across EU member states for dermatophyte indications
- UK MHRA, Health Canada, Australia TGA - All major Western regulators recognise griseofulvin
- WHO Essential Medicines List - Griseofulvin remains listed for dermatophyte infections in resource-limited settings
- DCGI (India) - Indian regulatory body for generic griseofulvin
- Original brand heritage - Wyeth-Ayerst (now Pfizer) developed Grisactin as one of the original branded griseofulvin formulations
- American Academy of Dermatology guidelines - Dermatophyte infection management
- British Association of Dermatologists guidelines - Tinea infection treatment standards
- European dermatology guidelines - Tinea capitis management approaches
- CDC fungal disease guidance - U.S. Centers for Disease Control recommendations
- WHO neglected tropical disease guidance - Dermatophyte management worldwide
- Pediatric dermatology guidelines - Tinea capitis in children (the main current indication)
- 60+ years of clinical experience - extensive established use in dermatophyte infections
- Cochrane systematic reviews - Multiple meta-analyses comparing griseofulvin to terbinafine and other antifungals
- Pediatric clinical trials - Substantial evidence for safety and efficacy in children
- UpToDate, DynaMed - Clinical decision support databases
- FDA FAERS, EMA EudraVigilance - Post-marketing safety surveillance
- Teratogenicity research - Established teratogenic risk; basis of pregnancy contraindication
- Drug interaction studies - Well-characterised CYP induction profile
Note: Grisactin and other griseofulvin brands are bioequivalent. The clinical evidence base applies equally to all griseofulvin products.
FAQ Reviewed and Referenced By:
The Medication Guide content for Grisactin reflects published research and clinical guidance from internationally recognised authorities in dermatology, pediatric dermatology, and nail-related mycology. All listed experts have substantial peer-reviewed publication records on antifungal therapy or related dermatology.
University of California San Diego / Rady Children's Hospital - San Diego, USA
Professor of Dermatology and Pediatrics at UC San Diego. Internationally recognised authority on pediatric dermatology including tinea capitis - the main current indication for griseofulvin. Past President of the Society for Pediatric Dermatology. Major contributor to clinical guidelines and trials of antifungal therapy in children.
George Washington University School of Medicine - Washington DC, USA
Professor and Chair of Dermatology at George Washington University. Active researcher and clinical educator on dermatologic infectious diseases including dermatophyte management. Frequent contributor to dermatology guidelines and educational content for practitioners.
Nail Disease Center - Cannes, France
Internationally recognised world authority on nail disorders including onychomycosis. Founder of the Nail Disease Center in Cannes. Author of foundational textbooks on nail disease. Decades of research on antifungal therapy for nail infections - one of the indications where griseofulvin retains historical importance.
Oregon Health and Science University - Portland, USA
Clinical Adjunct Professor of Dermatology at Oregon Health and Science University and Director of the Oregon Dermatology and Research Center. Leading nail dermatology researcher with extensive work on onychomycosis treatment and antifungal clinical trials.
University of Iceland - Reykjavik, Iceland
Professor of Dermatology at the University of Iceland and major contributor to onychomycosis research worldwide. Lead author of multiple landmark trials comparing antifungal therapies for nail infections. Long-term studies of treatment outcomes and recurrence patterns.
Note: this panel reflects published evidence and guidance from the listed authorities; it does not imply individual endorsement of this specific medication guide.






